HealthlineTwice-Monthly GLP-1 Shot Helps Manage Blood Sugar, Weight Loss in Trial

💊 Drug Development & Emerging Therapeutics

A randomized phase 2b study of 272 adults with type 2 diabetes evaluated bofanglutide, a GLP-1 receptor agonist administered every two weeks. Across dosing cohorts, participants experienced significant HbA1c reductions, weight loss, and improvements in cardiometabolic risk factors over 24 weeks.

Clinical Considerations

• Bofanglutide was evaluated as a biweekly injectable alternative to currently available once-weekly GLP-1 therapies.
• All bofanglutide treatment groups achieved significant HbA1c reductions from baseline through 24 weeks.
• Weight loss and favorable cardiometabolic changes accompanied glycemic improvements across treatment cohorts.
• Gastrointestinal adverse effects resembled those seen with other GLP-1 receptor agonists and were generally mild.

Practice Applications

• Recognize emerging interest in less-frequent GLP-1 dosing schedules.
• Interpret efficacy findings within the limitations of a phase 2b trial.
• Monitor forthcoming phase 3 and longer-term durability data.
• Consider population differences when applying findings outside studied cohorts.